79498-31-0 Usage
Uses
Used in Pharmaceutical Industry:
Glaucocalyxin A is used as an anti-tumor agent for its ability to inhibit the growth and proliferation of cancer cells, induce apoptosis, and cause cell cycle arrest. It is particularly effective against various types of cancer.
Glaucocalyxin A is used as an anti-inflammatory agent for its ability to suppress the production of inflammatory mediators, making it a potential candidate for the treatment of inflammatory diseases.
Used in Antimalarial Drug Development:
Glaucocalyxin A is used as a potential antimalarial drug candidate due to its potent anti-malarial activity, offering a new avenue for the development of treatments for malaria.
Check Digit Verification of cas no
The CAS Registry Mumber 79498-31-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,9,4,9 and 8 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 79498-31:
(7*7)+(6*9)+(5*4)+(4*9)+(3*8)+(2*3)+(1*1)=190
190 % 10 = 0
So 79498-31-0 is a valid CAS Registry Number.
InChI:InChI=1/C20H28O4/c1-10-11-5-6-12-19(4)8-7-14(21)18(2,3)13(19)9-15(22)20(12,16(10)23)17(11)24/h11-13,15,17,22,24H,1,5-9H2,2-4H3/t11?,12-,13+,15+,17?,19-,20?/m0/s1
79498-31-0Relevant academic research and scientific papers
Guo, Jiuzhou,Jia, Yanxing,Li, Bo,Ma, Weihao,Pitchakuntla, Mallesham
, p. 15195 - 15198 (2020)
A practically useful method for the formation of the highly oxygenated bicyclo[3.2.1]octane ring system through Mn(OAc)3-mediated radical cyclization of alkynyl ketones was developed, which opens up a new avenue for the total synthesis of a number of highly oxidized diterpenoids. Application of this method enabled the first total synthesis of (?)-glaucocalyxin A. Other salient features of the synthesis include a highly enantioselective conjugate addition/acylation cascade reaction, a Yamamoto aldol reaction, and an intramolecular Diels–Alder reaction to assemble the A/B ring system.
